Short-term follow-up: The 30-day observation period prevents assessment of permanent hypoparathyroidism (defined as PTH <15 pg/mL at 6 months), leaving the long-term protective effects of papaverine uncertain. The gene discussed is PTH; the disease is hypoparathyroidism.